BioSpace - Print News Article

Stevenage Bioscience Catalyst Sponsors Workshop at Biotech Showcase 2013 1/7/2013 12:45:44 PM Stevenage, UK, January 7 2013 – Stevenage Bioscience Catalyst (SBC), the UK’s first open innovation (OI) bioscience campus, will be debating the role of OI across the biotech and medtech sectors at the prestigious Biotech Showcase 2013 in San Francisco. In the workshop on January 9, 'Open Innovation: Driver of Future Healthcare Solutions?', CEO Martino Picardo will be joined by speakers from the venture capital and pharmaceutical industries. The panel, chaired by David Flores, President and CEO of Biocentury, is expected to cover issues such as how to use OI to tackle difficult research questions, as well as how to protect competitiveness and keep venture capital funders on board. Crowdfunding, the area of expertise for panellist Poliwogg Inc, and the latest OI initiatives will also be discussed. Other participants include GlaxoSmithKline, Syncona Partners (recently launched with £200m of initial capital from the Wellcome Trust), and PureTech Ventures. Biotech Showcase 2013 is an investor and partnering conference running from January 7-9 in parallel with the JP Morgan Healthcare Conference in San Francisco. It is expected to feature over 230 presentations, with in excess of 1500 attendees. For more information, please contact: Stevenage Bioscience Catalyst Martino Picardo, CEO +44 (0)1438 906906 Emma Palmer Foster, Strategic Communications Consultant +44 (0)7880 787185 comms@stevenagecatalyst.com About Stevenage Bioscience Catalyst Stevenage Bioscience Catalyst is the UK’s first open innovation bioscience campus, pioneering a unique culture to drive early stage bioscience technology and company development, and building a thriving community. It is backed by £38m of funding from its founding partners – GlaxoSmithKline, the Wellcome Trust, the Department for Business, Innovation and Skills, the Technology Strategy Board and the former East of England Development Agency. Consisting of an Incubator, an Accelerator and a Hub, covering 60,000 sq ft of laboratory, office and networking space, the independent facility houses a range of companies, from virtual and start-up firms to those which are more established, as well as other organisations. Located on the GlaxoSmithKline Stevenage site, Stevenage Bioscience Catalyst is in the unique position of operating in proximity to the expertise and resources of a major pharmaceutical company, close to both London and Cambridge. For more information, please go to www.stevenagecatalyst.com. About Open Innovation Firms using Open Innovation (OI) combine their own R&D with externally sourced ideas and expertise. OI is characterised by highly effective use of connections and networks to exchange knowledge and ideas, external partners being involved at all stages of product development, equitable win-win business relationships, and new business models to maximise the value of intellectual property and other assets. Examples in various sectors have shown that the benefits of OI include reduced time to market for new products and services, access to new markets, improved innovation success rates and increased profits. SBC will promote use of Open Innovation within the life sciences sector, connecting SMEs with an active network consisting of GlaxoSmithKline and its other stakeholders, academia, charities, other businesses and funding bodies. The term ‘Open Innovation’ and related research into its practice have been developed extensively by Professor Henry Chesbrough, Executive Director of the Program in Open Innovation at the University of California, Berkeley (http://openinnovation.berkeley.edu). About Stevenage Bioscience Catalyst's stakeholders Stevenage Bioscience Catalyst's stakeholders are GlaxoSmithKline (www.gsk.com), the Wellcome Trust (www.wellcome.ac.uk), the Department of Business, Innovation and Skills (www.bis.gov.uk), the Technology Strategy Board (www.innovateuk.org) and the former East of England Development Agency (www.eeda.org.uk)

Stevenage Bioscience Catalyst Sponsors Workshop at Biotech Showcase 2013
1/7/2013 12:45:44 PM

Stevenage, UK, January 7 2013 – Stevenage Bioscience Catalyst (SBC), the UK’s first open innovation (OI) bioscience campus, will be debating the role of OI across the biotech and medtech sectors at the prestigious Biotech Showcase 2013 in San Francisco. In the workshop on January 9, 'Open Innovation: Driver of Future Healthcare Solutions?', CEO Martino Picardo will be joined by speakers from the venture capital and pharmaceutical industries.

The panel, chaired by David Flores, President and CEO of Biocentury, is expected to cover issues such as how to use OI to tackle difficult research questions, as well as how to protect competitiveness and keep venture capital funders on board. Crowdfunding, the area of expertise for panellist Poliwogg Inc, and the latest OI initiatives will also be discussed. Other participants include GlaxoSmithKline, Syncona Partners (recently launched with £200m of initial capital from the Wellcome Trust), and PureTech Ventures.

Biotech Showcase 2013 is an investor and partnering conference running from January 7-9 in parallel with the JP Morgan Healthcare Conference in San Francisco. It is expected to feature over 230 presentations, with in excess of 1500 attendees.

For more information, please contact:

Stevenage Bioscience Catalyst

Martino Picardo, CEO +44 (0)1438 906906

Emma Palmer Foster, Strategic Communications Consultant +44 (0)7880 787185

comms@stevenagecatalyst.com

About Stevenage Bioscience Catalyst

Stevenage Bioscience Catalyst is the UK’s first open innovation bioscience campus, pioneering a unique culture to drive early stage bioscience technology and company development, and building a thriving community. It is backed by £38m of funding from its founding partners – GlaxoSmithKline, the Wellcome Trust, the Department for Business, Innovation and Skills, the Technology Strategy Board

and the former East of England

Development Agency. Consisting of an Incubator, an Accelerator and a Hub, covering 60,000 sq ft of laboratory, office and networking space, the independent facility houses a range of companies, from virtual and start-up firms to those which are more established, as well as other organisations. Located on the GlaxoSmithKline Stevenage site, Stevenage Bioscience Catalyst is in the unique position of operating in proximity to the expertise and resources of a major pharmaceutical company, close to both London and Cambridge. For more information, please go to www.stevenagecatalyst.com.

About Open Innovation

Firms using Open Innovation (OI) combine their own R&D with externally sourced ideas and expertise. OI is characterised by highly effective use of connections and networks to exchange knowledge and ideas, external partners being involved at all stages of product development, equitable win-win business relationships, and new business models to maximise the value of intellectual property and other assets. Examples in various sectors have shown that the benefits of OI include reduced time to market for new products and services, access to new markets, improved innovation success rates and increased profits. SBC will promote use of Open Innovation within the life sciences sector, connecting SMEs with an active network consisting of GlaxoSmithKline and its other stakeholders, academia, charities, other businesses and funding bodies. The term ‘Open Innovation’ and related research into its practice have been developed extensively by Professor Henry Chesbrough, Executive Director of the Program in Open Innovation at the University of California, Berkeley (http://openinnovation.berkeley.edu).

About Stevenage Bioscience Catalyst's stakeholders

Stevenage Bioscience Catalyst's stakeholders are GlaxoSmithKline (www.gsk.com), the Wellcome Trust (www.wellcome.ac.uk), the Department of Business, Innovation and Skills (www.bis.gov.uk), the Technology Strategy Board (www.innovateuk.org) and the former East of England Development Agency (www.eeda.org.uk)